Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

A. Munro, J.P. Codde, J.B. Semmens, Yee Leung, K. Spilsbury, V. Williams, N. Steel, Paul Cohen, H. Pavicic, V. Westoby, P.C. O'Leary

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.
    Original languageEnglish
    Pages (from-to)64-68
    JournalAustralian Family Physician
    Volume44
    Issue number1
    Publication statusPublished - 2015

    Fingerprint

    General Practitioners
    Cell Biology
    DNA
    Therapeutics
    Surveys and Questionnaires
    Referral and Consultation
    Education
    Squamous Intraepithelial Lesions of the Cervix

    Cite this

    Munro, A. ; Codde, J.P. ; Semmens, J.B. ; Leung, Yee ; Spilsbury, K. ; Williams, V. ; Steel, N. ; Cohen, Paul ; Pavicic, H. ; Westoby, V. ; O'Leary, P.C. / Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge. In: Australian Family Physician. 2015 ; Vol. 44, No. 1. pp. 64-68.
    @article{82016912431f417fbb255a7daab57b94,
    title = "Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge",
    abstract = "Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9{\%} response rate). A significant number (34.3{\%}) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.",
    author = "A. Munro and J.P. Codde and J.B. Semmens and Yee Leung and K. Spilsbury and V. Williams and N. Steel and Paul Cohen and H. Pavicic and V. Westoby and P.C. O'Leary",
    year = "2015",
    language = "English",
    volume = "44",
    pages = "64--68",
    journal = "Australian Family Physician.",
    issn = "0300-8495",
    publisher = "The Royal Australian College of General Practitioners",
    number = "1",

    }

    Munro, A, Codde, JP, Semmens, JB, Leung, Y, Spilsbury, K, Williams, V, Steel, N, Cohen, P, Pavicic, H, Westoby, V & O'Leary, PC 2015, 'Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge' Australian Family Physician, vol. 44, no. 1, pp. 64-68.

    Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge. / Munro, A.; Codde, J.P.; Semmens, J.B.; Leung, Yee; Spilsbury, K.; Williams, V.; Steel, N.; Cohen, Paul; Pavicic, H.; Westoby, V.; O'Leary, P.C.

    In: Australian Family Physician, Vol. 44, No. 1, 2015, p. 64-68.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge

    AU - Munro, A.

    AU - Codde, J.P.

    AU - Semmens, J.B.

    AU - Leung, Yee

    AU - Spilsbury, K.

    AU - Williams, V.

    AU - Steel, N.

    AU - Cohen, Paul

    AU - Pavicic, H.

    AU - Westoby, V.

    AU - O'Leary, P.C.

    PY - 2015

    Y1 - 2015

    N2 - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.

    AB - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.

    M3 - Article

    VL - 44

    SP - 64

    EP - 68

    JO - Australian Family Physician.

    JF - Australian Family Physician.

    SN - 0300-8495

    IS - 1

    ER -